|
CSSV, BCND, XDSL, MHYSE, NWBO, NWMT
Our Stocks to Watch today include Caspian Services Inc. (OTCBB: CSSV), Beacon Redevelopment Industrial Corp. (OTC: BCND), mPhase Technologies Inc. (OTCBB: XDSL), Mass Hysteria Entertainment Company Inc. (OTCBB: MHYSE), Northwest Biotherapeutics Inc. (OTCBB: NWBO) and NewMarket Technology Inc. (OTC: NWMT).
CASPIAN SERVICES INCORPORATED (OTCBB: CSSV)
"Up 100.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/CSSV.php
Caspian Services, Inc. provides various oilfield services for the oil and gas industry in western Kazakhstan and the Kazakhstan sector of the Caspian Sea. The company operates in three segments: Vessel Operations, Geophysical Services, and Marine Base Services. The Vessel Operations segment charters a fleet of shallow draft offshore support vessels to oil and natural gas exploration and production companies. Its vessel fleet includes supply vessels, seismic source and survey/utility vessels, anchor handling multicats and support vessel tugs, cable laying barges, accommodation vessels, and crewboats. The Geophysical Services segment offers onshore, transition zone, and marine seismic data acquisition services to independent oil and gas exploration and development companies operating in Kazakhstan and the Caspian Sea, as well as to the national oil company. The Marine Base Services segment operates a marine base located at the Port of Bautino on the North Caspian Sea. This segment offers various facilities and services comprising long and short terms vessel moorings, wharf front crane pad for vessel loading/offloading, boat yard with vessel lifting facilities, long-term berths, water storage facilities and vessel bunkering, oily and waste water collection and removing facilities, weighbridge facilities, electrical power supply and distribution systems, and open lay-down storage area. The company was formerly known as EMPS Corporation and changed its name to Caspian Services, Inc. in July 2005. Caspian Services, Inc. was founded in 1998 and is based in Almaty, Kazakhstan.
CSSV News:
No recent news for Caspian Services, Inc. (OTCBB: CSSV).
BEACON REDEVELOPMENT INDUSTRIAL CORP. (OTC: BCND)
"Up 40.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/BCND.php
Beacon specializes in acquiring undervalued properties that offer the potential for above average return on investment along with multiple assets and development ability at distressed prices. The properties must offer recyclable/salvageable materials along with the potential for redevelopment and or desirable development potential. The company also seeks, along with the above formentioned, properties that have the possibility for governmental grants, tax rebates or deferments as part of their criteria for acquisition. Please visit the company's Web site at www.beaconredevelopment.com for all the latest information and updates.
BCND News:
May 1 - Beacon Redevelopment Industrial Corporation Updates Shareholders as to Administrative Progress
Beacon Redevelopment Industrial Corporation (OTC: BCND) is advising the public and its shareholders of the current administrative progress previously announced.
BCND submitted Company required information to the Depository Trust & Clearing Corporation (DTCC) so that they may update their files.
The Company also submitted all required information to OTC Markets, Inc. for the purpose of publishing current financial statements and disclosures per their requirements.
Finally, management retained an accountant who will diligently oversee all requirements regarding current financial statements and other filings.
BCND is reviewing the quickest way to demolish and rehabilitate its Westmoreland Glass Factory property in Grapeville, Pennsylvania. The factory remains under the ownership of BCND's subsidiary, Beacon Pennsylvania Holdings. The Company's first order of business after completion of all outstanding administrative issues is to move forward with deconstructing the factory and the salvage of all valuable recyclable materials.
While prior management had a plan in place, they were unable to accomplish their goals because of distractions that impeded the program. "I will be personally mobilizing a team for this job so that we can enhance shareholder value, generate Corporate profits, and achieve real results," said Frank Castellano, President of Beacon Redevelopment.
MPHASE TECHNOLOGIES INCORPORATED (OTCBB: XDSL)
"Up 37.50% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/XDSL.php
mPhase Technologies, Inc. is focused on developing and commercializing a new battery technology featuring Power On Command™ which provides a unique way to store energy and manage power that will revolutionize the battery industry. mPhase, through its 100% owned consumer products division mPower Technologies, is marketing its first Power On Command product, the mPower Emergency Illuminator.
XDSL News:
No recent news for mPhase Technologies, Inc. (OTCBB: XDSL).
MASS HYSTERIA ENTERTAINMENT COMPANY (OTC: MHYSE)
"Up 42.86% on Tuesday"
Detailed Quote: www.otcpicks.com/quotes/MHYSE.php
Mass Hysteria Entertainment Company, Inc., a motion picture studio, produces branded young adult film content for theatrical, DVD, and television distribution. It intends to produce ‘Mass Hysteria’ branded comedy films that screen only at midnight on Fridays and Saturdays. The company focuses on the provision of a hybrid entertainment that uses movies as a destination and combines them with hand-held devices, the Internet, and live theater. It was formerly known as Michael Lambert, Inc. and changed its name to Mass Hysteria Entertainment Company, Inc. in July 2009 to reflect its new business plan to produce theatrical films for the youth market. The company was founded in 2005 and is headquartered in Hollywood, California.
MHYSE News:
No recent news for Mass Hysteria Entertainment Company, Inc. (OTCBB: MHYSE).
NORTHWEST BIOTHERAPEUTICS INCORPORATED (OTC: NWBO)
"Up 21.43% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/NWBO.php
Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company is developing dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax®-L for recurrent metastatic ovarian cancer.
NWBO News:
May 1 - Northwest Bio Awarded $5.5 Million German Government Grant
Funding for Manufacturing and for Brain Cancer Trial At 30 Sites In Germany
Northwest Biotherapeutics, Inc. (OTCBB: NWBO) (NW Bio) announced that, working together with the Fraunhofer Institute (IZI), it has received approval of a major grant from the Sachsische Aufbau Bank (SAB or Saxony Development Bank) in Germany. The grant will reimburse fifty percent (50%) of the costs for manufacturing in Germany and for NW Bio's clinical trial with DCVax®-L for brain cancer at up to 30 clinical sites in Germany. The amount of the grant will be euro 4.15 million (about $5.5 million).
The clinical sites in Germany and their data will become part of the 240-patient, double blind, randomized, placebo-controlled clinical trial for newly diagnosed Glioblastoma multiforme (GBM) brain cancer, which is under way at more than 30 sites across the U.S. The German clinical sites and data will also provide domestic data for European Union (EU) approval processes.
"After working closely for more than 7 months on this grant application process with partners at Fraunhofer IZI, Bioville GmbH, the Translational Center for Regenerative Medicine and Cognate GmbH, we are excited and honored to be awarded one of the largest such R&D grants ever made by the Saxony Development Bank," commented Linda Powers, CEO of NW Bio. "This award will help us build our base in Germany, and accelerate our brain cancer clinical trial in Europe as well as the US, with some of the most respected institutions on both sides of the Atlantic."
As noted last week, following recent completion of 13 months of technology transfer and regulatory processes for certification of DCVax®-L manufacturing in Germany, the final regulatory inspection of Fraunhofer IZI's manufacturing facility is scheduled for June. After the final inspection is successfully completed, manufacturing for the DCVax®-L clinical trial and for Hospital Exemption cases under subsection 4b of the German Drug Act (i.e., compassionate use cases) will be ready to begin. To date, 24 of the 30 clinical trial sites in Germany have already been selected and are in varying stages of qualification and preparation.
NW Bio has made a strategic decision to settle in Leipzig, Germany, and establish its subsidiary there. Leipzig is the second largest city in the State of Saxony, and is the home of Fraunhofer IZI. The State of Saxony, and Leipzig in particular, have put a concentrated focus on regenerative medicine and cell therapies (including immune therapies) for nearly a decade, and have become one of the most important centers for such therapies in Europe. This concentration includes the full spectrum of capabilities and infrastructure, from R&D to specialized hospitals and medical centers to manufacturing. Funding for the grant has been provided by the German Federal State of Saxony and the European Union.
Leipzig has also become a leading center for Europe-wide logistics. DHL, a dominant courier service in Europe, recently moved its overall European logistics hub from Belgium to Leipzig. Other general logistics companies, such as Lufthansa Cargo, and specialized couriers, such as World Courier (who specializes in handling and transporting human organs, tissues and blood products), have also established major operations in Leipzig.
With the support of the State of Saxony, NW Bio will have the opportunity to expand its development and long-term marketing activities for DCVax®-L in Europe.
NEWMARKET TECHNOLOGY INCORPORATED (OTC: NWMT)
"Up 100.00% on Tuesday"
Detailed Quote: http://www.otcpicks.com/quotes/NWMT.php
NewMarket's current portfolio of operating subsidiaries provides systems integration and technology infrastructure services. NewMarket's operations strategically focus on providing technology and support services in emerging and developing economies with high growth rate potential. NewMarket has operating subsidiaries today in China, Singapore, Brazil and Northern Latin America.
NWMT News:
April 5 - NewMarket Technology, Inc. Announces Chairman Resignation
NewMarket Technology, Inc. (OTC: NWMT) announced that Philip Verges resigned on Friday, March 30th as Chairman of the Board. The resignation was executed in conjunction with a strategic business plan update previously announced on October 20th 2011.
Mr. Verges plans to expand his current role with the United Nations and dedicate more time to personal projects already underway, both focused on improving the capital markets for small and medium businesses worldwide with a special concentration on emerging markets.
|
